We demonstrated that human ER+ breast cancer cells with a point mutation in the ligand binding domain of ESR1 (encodes ER) had increased expression of CHI3L1 when compared to those with wild type ESR1 [175]. This evidence concerns the gene CHI3L1 and breast carcinoma.